pr-inside.com
Print

MagForce starts research project with University of Bremen



2013-01-31 10:07:38 -


MagForce AG /
MagForce starts research project with University of Bremen
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

* Project to develop magnetic iron oxide particles with improved efficiency
* Agreement on funding by German Federal Ministry of Economics and Technology
from the German Mittelstand innovation program "Zentrales
Innovationsprogramm Mittelstand (ZIM)"

Berlin, Germany, January 31, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a
leading medical technology company in the field of nanomedicine in oncology,
today announced the start of a research project with the University of Bremen,
Center for Environmental Research and Sustainable Technology, for the
development of magnetic iron oxid particles with improved efficiency. The novel
particles will allow a more efficient treatment of abdominal cancers, such as
prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot
manufacturing facility will result from the collaboration.
The project will receive funding from the German Mittelstand Innovation Program
(ZIM) which is managed by the German Federal Ministry of Economics and
Technology and will run for two years.
"We are excited to be working with Prof Dr Jorg Thöming, who is an
internationally renowned expert in the area of process engineering, as a
cooperation partner. This project is perfectly in-line with MagForce's new
strategy to conduct early-stage research and development collaborations with
academic institutions", commented Prof Dr Hoda Tawfik, COO and co-CEO of
MagForce AG. "In August 2012, we temporarily put all internal early-stage
research and development on hold to focus the Company's resources on
establishing our NanoTherm® therapy in the market. This project gives us the
opportunity to develop the next generation of NanoTherm® that will significantly
improve the treatment of abdominal cancers." Prof Dr Jorg Thöming comments: "I
am excited to start the collaboration in the nanotechnology area with MagForce,
an innovative nanomedicine company. The exploitation of synergies between our
scientists is very promising."
About MagForce AG
MagForce AG is a leading medical technology company in the field of nanomedicine
in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted
treatment of solid tumors through the intratumoral generation of heat via
activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and
NanoActivator(TM) are components of the therapy and have received EU-wide
regulatory approval as medical devices for the treatment of brain tumors.
MagForce, NanoTherm®, NanoPlan®, and NanoActivator(TM) are trademarks of
MagForce AG in select countries. For more information, please visit
www.magforce.com.

Disclaimer
This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects", "aims",
"anticipates",
"intends", "plans", "believes", "seeks",
"estimates" or "will". Such forward-
looking statements are based on our current expectations and certain
assumptions, which may be subject to a variety of risks and uncertainties. The
results actually achieved by MagForce AG may substantially differ from these
forward-looking statements. MagForce AG assumes no obligation to update these
forward-looking statements or to correct them in case of developments, which
differ from those, anticipated.

Contact:
Anne Hennecke
MC Services AG

T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759

Email: anne.hennecke@mc-services.eu


MagForce_Press Release_Jan 31, 2013:
hugin.info/143761/R/1674480/545259.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MagForce AG via Thomson Reuters ONE
[HUG#1674480]


Press Information:




Contact Person:


Phone:
email: e-mail




Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.